Skip to main content
Caplight Logo









OrsoBio

OrsoBio

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://orsobio.com/

Last Round

Series B

Sep 6, 2024

Total Funding Raised

$166.3M

Company Overview

OrsoBio is a biopharmaceutical company that develops first-in-class therapies to treat severe metabolic disorders, including obesity, type 2 diabetes, MASH, and severe dyslipidemia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmetabolic diseasesmall-molecule therapeuticsdrug discoveryclinical trialsbiotechNASHnon-alcoholic steatohepatitismitochondrial functionlipid metabolismACC2 inhibitordrug pipelineobesity treatmentclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OrsoBio Comparables

Compare OrsoBio with similar companies based on industry and business-model similarity.

OrsoBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rivus Pharmaceuticals
86%
Eolo Pharma
79%
AdipoPharma
78%

OrsoBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 6, 2024
Series ANov 7, 2023
GrantNov 2, 2022
SeedNov 1, 2022

Key People

Founding team and executive leadership

G. Mani Subramanian

CEO

Executive Team

Gans Ganapati

Chief Financial Officer

Executive Team

OrsoBio Investors

Notable investors and investment history

OrsoBio investors
InvestorRounds
Longitude CapitalSeries B, Series A
Enavate SciencesSeries B, Series A
National Institute of Diabetes and Digestive and Kidney DiseasesGrant
Samsara BioCapitalSeries A, Series B, Seed
Woodline PartnersSeries B
NuevaBioSeries A, Seed, Series B
Ascenta CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 79% MoM, reaching 3.8K.

  • Sep 6, 2024

    $67M round led by Ascenta Capital.

OrsoBio Filings

Explore SEC and related filing metadata, where available.

OrsoBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about OrsoBio's valuation, stock price, and market status.

Is OrsoBio a public or private company?

OrsoBio is a private company.

What is the current stock price of OrsoBio?

OrsoBio is a private company with no public stock price. No recent secondary market data is available.

How much is OrsoBio worth (valuation)?

Valuation information for OrsoBio is not publicly available.

Can I buy OrsoBio stock?

OrsoBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was OrsoBio's last funding round?

OrsoBio's most recent funding round was Series B on September 6, 2024.

Who are the main investors in OrsoBio?

Key investors in OrsoBio include Longitude Capital, Enavate Sciences, Samsara BioCapital, Ascenta Capital.

Will OrsoBio IPO soon?

No public IPO plans have been announced for OrsoBio.

How can I track OrsoBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OrsoBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range13
Year Founded2020
Last FundingSep 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?